Romiplostim injection bulk supplier for pharma manufacturers

Romiplostim Injection 250mcg/vial, 500 mcg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 250mcg/vial, 500 mcg/vial

Reference Brands: Nplate®(US & EU)

Romiplostim is a thrombopoietin receptor agonist that stimulates platelet production by activating the TPO receptor on megakaryocytes. It increases platelet counts, reducing bleeding risk in chronic immune thrombocytopenic purpura (ITP). Benefits include improved blood cell counts, decreased bleeding episodes, and enhanced quality of life for patients with thrombocytopenia.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Romiplostim injection, marketed as Nplate®, is approved by the FDA and EMA for treating chronic immune thrombocytopenic purpura (ITP). Regulatory dossiers include comprehensive clinical trial data, manufacturing standards, and safety profiles, ensuring high-quality product approval. The dossiers support its efficacy in increasing platelet counts and reducing bleeding risk. Nplate® is administered as a subcutaneous injection, with dosing tailored to patient needs. For detailed information on regulatory processes, dossier submissions, and market approvals in the EU and US, visit PharmaTradz, your trusted source for pharmaceutical regulatory insights and industry updates.

Romiplostim Injection — third party manufacturing & bulk supply

Romiplostim Injection 250mcg/vial, 500 mcg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Romiplostim Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Romiplostim Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Romiplostim Injection →

Back to Listing

Frequently Asked Questions

Romiplostim injection is listed as Injection in 250mcg/vial, 500 mcg/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Romiplostim injection is referenced against Nplate®(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.